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A single high dose of dexamethasone affects the
phosphorylation state of glutamate AMPA receptors
in the human limbic system
MW Lopes1,16, RB Leal1,2,16, R Guarnieri2,3,4, ML Schwarzbold2,5, A Hoeller1, AP Diaz2,5, GL Boos6, K Lin2,3,5, MN Linhares2,4,7, JC Nunes8,
J Quevedo9,10,11, ZA Bortolotto12,13, HJ Markowitsch14, SL Lightman13,15 and R Walz2,3,5
Glucocorticoids (GC) released during stress response exert feedforward effects in the whole brain, but particularly in the limbic
circuits that modulates cognition, emotion and behavior. GC are the most commonly prescribed anti-inflammatory and
immunosuppressant medication worldwide and pharmacological GC treatment has been paralleled by the high incidence of acute
and chronic neuropsychiatric side effects, which reinforces the brain sensitivity for GC. Synapses can be bi-directionally modifiable
via potentiation (long-term potentiation, LTP) or depotentiation (long-term depression, LTD) of synaptic transmission efficacy, and
the phosphorylation state of Ser831 and Ser845 sites, in the GluA1 subunit of the glutamate AMPA receptors, are a critical event for
these synaptic neuroplasticity events. Through a quasi-randomized controlled study, we show that a single high dexamethasone
dose significantly reduces in a dose-dependent manner the levels of GluA1-Ser831 phosphorylation in the amygdala resected
during surgery for temporal lobe epilepsy. This is the first report demonstrating GC effects on key markers of synaptic
neuroplasticity in the human limbic system. The results contribute to understanding how GC affects the human brain under
physiologic and pharmacologic conditions.
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INTRODUCTION
Stress responses initiated by environmental threats promote
autonomic, endocrine, and behavioral changes that help self-
preservation.1 The prefrontal cortex (PFC), amygdala (AMY) and
hippocampus (HIP) are the key brain structures of the feedforward
and feedback networks that mediate states of stress and fear.
Glucocorticoids (GC) released during stress responses have
feedforward effects in the whole brain, with a particular impor-
tance in limbic structures.1,2 During non-stress conditions, the PFC
exerts top–down regulation of limbic structures including the
AMY, but in acute stress bottom–up processes prevail and
behavior changes from slower, highly flexible responses to faster,
stereotyped reaction.3 Stress can be helpful or harmful depending
on its intensity, duration and personal features.2,4 In predisposed
individuals acute and intense stress has been associated with
post-traumatic stress disorder,2,4 and chronic and repetitive stress
with other psychiatric disorders, including anxiety and mood
disorders.2,5 In rodents the stress and excessive GC release reduce
synaptic plasticity and dendritic spines in the PFC and HIP, impairs
hippocampal neurogenesis, and increase synaptic plasticity and
dendritic alterations in the AMY, which has been associated with
behavioral abnormalities.5–7 In humans, evidence correlates the
morphological, metabolic, functional, and cognitive effects of GC
on limbic structures.8–12 The brain sensitivity to GC, particularly the
limbic system, may contribute to the high incidence of GC-related
neuropsychiatric side effects.13 Furthermore, increased endogen-
ous GC levels in Cushing’s syndrome are commonly associated
with depression, mania and anxiety.14,15
Dependent on the applied stimulation frequency, active synapses
are bi-directionally modifiable in mammalian brain regions such as
the AMY, HIP and neocortex.16–18 The long-lasting increase of
synaptic transmission, called long-term potentiation (LTP), is
induced by high-frequency neuronal stimulation.16,18–21 Decreases
in synaptic efficacy are also needed to reset the synapses, and are
accounted by long-term depression (LTD), after low-frequency
stimulation.16–18 Pharmacological evidence ‘in vivo’ suggests an
association between LTP and one-trial inhibitory avoidance,22–24 a
fear associative memory task that induces LTP in the HIP.25 The
fear conditioning, another fear associative memory task, can be
inactivated and reactivated by LTD and LTP in the AMY,
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supporting a causal link between these synaptic processes and
memory.18 Memory consolidation for both these tasks also can be
modulated by GC.1,6,26–28
AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)
receptors (AMPARs) are heterotetrameric assemblies of GluA1–
GluA4 subunits, usually permeable to Na+ and K+. Expression of
Ca2+-permeable AMPARs, lacking GluA2 subunits (that is, GluA1
homomers) exist especially in the extrasynaptic and intracellular
locations but can be recruited to synapses during
neuroplasticity.29 Phosphorylation and dephosphorylation states
of distinct sites of the GluA1 subunit of the AMPAR regulates the
channel conductance and GluA1 synaptic membrane insertion is
involved in the LTP and LTD induction.29–34 Two major sites of
GluA1 phosphorylation of AMPAR are studied regarding their role
in neuroplasticity: (1) the Ser831, phosphorylated by Ca2+/calmo-
dulin-dependent protein kinase II (CaMKII) and protein kinase C
(PKC), which increases the channel conductance; (2) the Ser845,
phosphorylated by cAMP-dependent protein kinase (PKA) that
affects the open-channel probability of the receptor and
regulates the synaptic incorporation of GluA1 subunit of AMPARs.
It was reported that in naive synapses, LTD induction depho-
sphorylates Ser845, although in potentiated synapses the Ser831
is dephosphorylated by LTD induction. Conversely, LTP induction
in naive synapses increases phosphorylation of GluA1-Ser831,
whereas in depressed synapses phosphorylation of GluA1-Ser845
was enhanced.34 Serine 845 and 831 are dephosphorylated by
low-frequency stimulation (LTD) in a manner dependent of
protein phosphatase activity including PP1, PP2A and
PP2B.32,35,36 Mice generated with knockin mutations in the GluA1
phosphorylation sites that shows deficits in LTD and LTP in the
CA1 region of Hippocampus and have memory defects in spatial
learning tasks. These results demonstrate that phosphorylation of
GluA1 is critical for LTD and LTP expression and is involved in
memory processing.37 Therefore, GluA1 phosphorylation of
AMPARs sites at Ser831 and Ser845 sites are critical for ‘in vivo’
synaptic plasticity being an emerging focus as a major target for
stress and GC in the limbic system.38–40
The GC effects on the phosphorylation state of GluA1-AMPA,
has never been investigated in the human limbic system. Mesial
temporal lobe epilepsy related to hippocampal sclerosis (MTLE-HS)
is the most common surgically remediable epileptic syndrome.41
Because surgery involves a ‘standard’ resection of the neocortical
and mesial temporal lobe structures,41 it offers an ethical
opportunity to obtain human samples of AMY and HIP under
well-controlled conditions to investigate phosphorylation state of
proteins. Here we present a quasi-randomized controlled study
showing the effect of a single high dose of dexamethasone (DEXA),
on the phosphorylation levels of GluA1-Ser845 and GluA1-Ser831 in
the human AMY, head of HIP and middle temporal neocortex gyrus
(CX) of surgical patients with drug resistant MTLE-HS.
MATERIALS AND METHODS
Patients
We included 31 adult drug-resistant MTLE-HS patients treated surgically
between May 2009 and December 2012 at the Centro de Epilepsia de
Santa Catarina. They participated in a prospective study about synaptic
plasticity markers in MTLE-HS. All patients had seizures that impaired
awareness at least once a month (mean 7.5 per month), despite adequate
treatment with at least two antiepileptic drugs (AEDs) in monotherapy.
Their medical history, seizure semiology, neurological examination,
psychiatric and neuropsychological evaluation, interictal and ictal surface
video-EEG, and magnetic resonance imaging findings were consistent with
unilateral MTLE-HS.41–47
Controlled clinical variables included gender, race, side of HS, age,
disease duration, age of recurrent seizures onset, psychiatric comorbidities
and quality of life.41–47 The AEDs used were carbamazepine, phenobarbital,
diphenilhydantoin, valproic acid, lamotrigine or topiramate, associated or
not with benzodiazepines (clobazam or clonazepam). The protocol was
approved by the Ethics Committee for Human Research of Universidade
Federal de Santa Catarina (365-FR304969). Written informed consent was
obtained from all patients.
Anesthesia protocol
The anesthetic protocol, except the DEXA treatment, were the same for all
patients. Anesthesia started between 0730 hours to 0830 hours with
intravenous (i.v.) bolus of propofol (2 mg kg− 1), fentanyl (2 μg kg− 1) and
rocuronium (0.9 mg kg− 1), followed by i.v. remiphentanil infusion (0.1 to
0.2 μg kg− 1 min) and isofluorane inhalation (0.5 to 0.6 M.A.C.). Hydration
was done with isotonic saline (1.2 ml kg− 1 h) plus the half volume of
diuresis. Cephalotine (30 mg kg− 1) was given 30 min before the anesthe-
sia. Oral AEDs were maintained until the day of surgery (0600 hours).
Patients received 20 mg kg− 1 of phenytoin i.v. 12 h before the surgery and
5 mg kg− 1 i.v. after the brain samples were collected. Patients under
phenytoin at home received only their morning oral dose and the
intraoperative dose after the brain samples were collected.
Dexamethasone treatment and study design
After the first 11 patients were included in the study, the anesthesiology
team decided to use DEXA (10 mg i.v. bolus) immediately after intubation
as an adjunctive anti-inflammatory and anti-emetic therapy.48 The DEXA
infusion was not based on any clinical data. This change in the anesthesia
protocol gave us the opportunity to design this quasi-randomized controlled
study. The DEXA dose was calculated dividing 10 mg by the patient weight.
The mean (s.e.) DEXA dose was 0.1575 (0.006) mg kg−1 (range 0.11 to 0.2).
Although this selective GR agonist differs from endogenous cortisol in many
aspects of its transcriptional activity, this dose results in at least 27 times the
effect of a daily adult human secretion of cortisol.49
Surgery, intraoperative variables and brain tissue sampling
The surgeries and tissue sampling were done by the same neurosurgeon
(MNL) and the principal investigator (RW) as previously described.50 The
samples came from the brain tissue removed during a standard anterior
and temporal lobectomy (ATL) procedure and were immediately frozen in
liquid nitrogen and stored in − 80 oC freezer until the analyses. The
sampling course is presented in Supplementary Figure 1. The temporal
lobe resection included the middle and inferior temporal gyri extended up
to 4 cm posterior from the temporal pole. Prior to the cortical resection, a
1 cm2 sample of the CX localized 3 cm posterior to the temporal pole was
gently dissected from the white matter. After assessing the mesial
temporal region, 2/3 of the AMY were collected including its basal and
the lateral nucleus. Both AMY and CX were collected without previous
thermocoagulation. After AMY resection, the HIP was removed ‘en bloc’
and its head and part of the body were quickly dissected on ice-
refrigerated glass. The time of HIP manipulation since the electrocoagula-
tion of its vascular supply start until its resection was controlled. Arterial
blood gases, electrolytes, hematocrit, hemoglobin, acid-basic, mean arterial
pressure heart and respiratory rate parameters during the AMY/HIP
sampling were controlled. The anesthesia duration until each brain sample
was controlled as well. The hemodynamic and respiratory parameters
remained stable and no surgical complication was reported.
Biochemical analysis
Biochemical analysis was blinded for all clinical data. All samples were
homogenized by the same researchers (MWL) in the same day, placed in
liquid nitrogen, and storage at − 80 oC until the analysis. The quantification
of phosphorylation levels and total amount of the target proteins were
performed by western blot as we described previously.51–56 Protein
content was determined by Peterson’s method.57 Proteins were detected
after overnight incubation with specific antibodies diluted in TBS with
tween with 2% bovine serum albumin in a 1:1000 dilution (anti-phospho-
GluA1-Ser831 (Sigma-Aldrich, St Louis, MO, USA, A4352); anti-phospho-
GluA1-Ser845 (Sigma-Aldrich, A4477); anti-total-GluA1 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA, sc-13152); anti-EAAT1 (Cell Signaling,
Beverly, MA, USA, #5684); anti-EAAT2 (Cell Signaling,#3838); anti-PP1ca
(Santa Cruz Biotechnology,sc-7482); anti-phospho-CaMKII (Cell Signaling,
#3361); anti-total-CaMKII (Cell Signaling, #3362); anti-GFAP (Cell Signaling,
#3670) and anti-total-AKT (Cell Signaling, #9272)); 1:2000 (anti-phospho-
ERK1/2 (Sigma-Aldrich, M8159); anti-phospho-AKT (Sigma-Aldrich, P4112);
anti-phospho-PKA substrates (Cell Signaling, #9624) and anti-phospho-PKC
substrates (Cell Signaling, #2261)), 1:5000 (anti-phospho-JNK p54/46
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Table 1. Clinical, demographic, neuroradiological, neurophysiological and surgical variables of patients with mesial temporal lobe epilepsy related to
hippocampal sclerosis according to dexamethasone treatment
Variables All cases, n=31 No dexamethasone, n= 11 Dexamethasone, n= 20 P-value
Gender
Female 18 (58.1) 4 (36.4) 14 (70.0)
Male 13 (41.9) 7 (63.6) 6 (30.0) 0.13
Race
Caucasian 27 (87.1) 9 (81.8) 18 (90.0)
Others 04 (12.9) 2 (16.2) 2 (10.0) 0.60
Marital status
Single 17 (54.8) 8 (72.7) 9 (45.0)
Married 10 (32.3) 2 (18.2) 8 (40.0)
Divorced or widower 4 (12.9) 1 (9.1) 3 (15.0) 0.33
Current work activity
Working 11 (35.5) 4 (36.4) 7 (35.0)
Health insurance 4 (12.9) 7 (63.6) 9 (45.0)
Not working 16 (51.6) 0 (0.0) 4 (20.0) 0.26
History of initial precipitant injury
No 7 (22.6) 3 (27.3) 4 (20.0)
Yes 24 (77.4) 8 (72.7) 16 (80.0) 0.68
Family history of epilepsy
No 12 (38.7) 4 (36.4) 8 (40.0)
Second-degree or distant 10 (32.3) 2 (18.2) 8 (40.0)
First- degree 6 (19.4) 3 (27.3) 3 (15.0)
Unknown 3 (9.7) 2 (18.2) 1 (5.9) 0.41
MRI hippocampal sclerosis
Right side 16 (51.6) 4 (36.4) 12 (60.0)
Left side 15 (48.4) 7 (63.6) 8 (40.0) 0.27
Antiepileptic drugs regimena
Monotherapy 9 (29.0) 6 (54.5) 3 (15.0)
Two or more drugs 23 (71.0) 5 (45.5) 17 (85.0) 0.04
Benzodiazepines
Yes 15 (48.4) 7 (63.6) 9 (45.0)
No 16 (51.6) 4 (36.4) 11 (55.0) 0.46
Antiepileptic drugs
Carbamazepine
No 6 (19.4) 4 (36.4) 2 (10.0)
Yes 29 (80.6) 7 (63.3) 18 (90.0) 0.16
Phenobarbital
No 19 (61.3) 9 (81.2) 10 (50.0)
Yes 12 (38.7) 2 (18.2) 10 (50.0) 0.13
Diphenilhydantoin
No 28 (90.3) 11 (100.0) 17 (85.0)
Yes 3 (9.7) 0 (0.0) 03 (15.0) 0.54
Valproic acid
No 29 (93.5) 9 (81.8) 18 (90.0)
Yes 4 (12.9) 2 (18.2) 2 (10.0) 0.60
Lamotrigin
No 27 (87.1) 9 (81.8) 18 (90.0)
Yes 4 (12.9) 2 (18.2) 2 (10.0) 0.60
Topiramate
No 29 (93.5) 11 (100.0) 18 (90.0)
Yes 2 (6.5) 0 (0.0) 2 (10.0) 0.53
Hand dominance
Right 27 (87.1) 9 (81.8) 18 (90.0)
Non-right 4 (12.9) 2 (18.2) 2 (10.0) 0.60
Psychiatric comorbidities
No diagnosis 14 (45.2) 4 (36.3) 10 (50.0)
Depressive disorder 8 (25.8) 2 (18.2) 6 (30.0)
Anxiety disorderb 3 (9.7) 2 (18.2) 1 (5.0)
Other psychiatric conditionsc 6 (19.4) 3 (27.3) 3 (15.0) 0.48
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(Sigma-Aldrich, J4750) and anti-total-JNK p54/46 (Sigma-Aldrich, J4500));
1:10 000 (anti-phospho-p38MAPK (Merck-Millipore, Temecula, CA, USA,
05-1059) and anti-total-p38MAPK (Sigma-Aldrich, M0800)) and 1:40 000
(anti-total-ERK1/2 (Sigma-Aldrich, M5670)). All membranes were incubated
with anti-β-actin (Santa Cruz Biotechnology, sc-47778, 1:2000) antibody to
control the protein load for each sample on the gel. The phosphorylation
level was determined as a ratio of the optic density (OD) of the phos-
phorylated band/the OD of the total band. The immunocontent was
determined as a ratio of the OD of the protein band by the OD of the
β-actin band. The bands were quantified using the Scion Image
software (Frederick, MD, USA).
Owing to the lack of adequate brain tissue samples from healthy
controls and to avoid intra-day biases of western blot quantification, an
internal control (IC) coming from three pooled HIP homogenized in the
same way and time as all the studied samples was applied in all
electrophoresis. The strategy also allows comparisons of variations in the
phosphoprotein percentage according to brain structures and clinical
parameters among the patients. The OD ratio (phospho/total or total/β-
actin) for each target protein in the IC was considered 100%. The OD ratio
of each protein analyzed in the samples was correlated as a percentage of
the IC. When ERK1 phosphorylation was analyzed, for example, and the OD
ratio (OD phospho-ERK1/OD total-ERK1) of the IC was 0.75 and the OD ratio
for the investigated sample was 0.9; this means that the OD ratio of the
investigated sample was 120% of the IC.
Statistical analysis
All the neurochemical and clinical variables showed a parametric
distribution (Kolmogorov–Smirnov). The distribution of neurochemical,
clinical and laboratory variables according to DEXA treatment were
analyzed by the Student’s t-test, analysis of variance or Fisher’s exact test.
Comparisons of GluA1-Ser831 and GluA1-Ser845 phosphorylation levels in
the CX, AMY and HIP between patients who received or not DEXA
treatment were analyzed by Student’s t-test. To reduce the possibility of a
type I error due to multiple comparisons (two GluA1 phosphorylation sites
in three structures) the level of significance should be Po0.0085. Multiple
linear regressions analyses were done to determine the independent effect
of DEXA on the variation of the phosphorylation levels of the serine 831
and 845 of the GluA1 subunit of glutamate AMPARs. Variables showing
associations with Po0.15 in the univariate analysis were included in the
multiple linear regressions analysis. For the final regression model the
Po0.01 were considered statistically significant.
RESULTS
Table 1 shows the clinical, demographic, and laboratory variables
of patients according to DEXA treatment. There were trends for
imbalances between DEXA and non-DEXA groups according to
gender (P= 0.13), AEDs regimen (P= 0.04), phenobarbital use
(P= 0.13), monthly frequency of seizures (P= 0.04), intraoperative
serum glucose (P= 0.10) and storage time of samples (P= 0.05).
The phosphorylation profile according to DEXA groups is shown
in Table 2. The AMY levels of P-GluA1-Ser831 were 20.9% lower in
the DEXA-treated patients in comparison with non-DEXA group
(P= 0.0003). There were trends for lower levels of P-GluA1-Ser831
in the CX (P= 0.06) and HIP (P= 0.10) among patients treated with
Table 1. (Continued)
Variables All cases, n= 31 No dexamethasone, n= 11 Dexamethasone, n= 20 P-value
Mean (s.e.)
Age (years) 36.4 (2.2) 34.6 (3.8) 37.3 (2.7) 0.57
Education (years) 6.6 (0.5) 6 (1.0) 6.9 (0.6) 0.43
Disease duration (years) 24.3 (2.0) 25.8 (3.1) 23.5 (2.6) 0.60
Monthly seizure frequency 7.5 (0.9) 4.9 (0.9) 8.5 (1.1) 0.04
QOLIE-31 35.2 (2.7) 38.2 (3.8) 33.5 (3.7) 0.43
Intraoperative parameters
Mean arterial pressure 67.5 (1.7) 64 (3.0) 68.8 (2.1) 0.30
Heart rate 73.7 (2.2) 70 (4.1) 75 (2.7) 0.30
Respiratory frequency 11.6 (0.3) 11.7 (0.5) 11.5 (0.4) 0.88
Biochemical analysis of the blood
pH 7.41 (0.07) 7.41 (0.01) 7.42 (0.01) 0.66
PCO2 28 (0.8) 29.6 (1.5) 28.1 (0.9) 0.35
HCO3 20.0 (0.3) 20.7 (0.6) 19.6 (0.3) 0.20
PO2 229 (11.0) 214.6 (25.1) 237.8 (10.3) 0.32
O2 saturation 99.7 (0.04) 99.6 (0.08) 99.7 (0.05) 0.90
Hematocrit 35.0 (0.7) 33.9 (1.4) 35.6 (0.8) 0.27
Hemoglobin 12.5 (0.9) 14.9 (2.9) 11.7 (0.3) 0.26
Glucose 116.3 (4.9) 103.4 (6.4) 121 (6.0) 0.10
Sodium 138.2 (3.9) 136.9 (1.2) 139 (1.7) 0.20
Potassium 4.1 (0.1) 4.2 (0.2) 4.1 (0.1) 0.63
Ionic calcium 4.2 (0.1) 4.1 (0.1) 4.2 (0.2) 0.95
Magnesium 0.4 (0.08) 0.4 (0.02) 0.5 (0.01) 0.15
Lactic acid 2.1 (0.2) 1.7 (0.3) 2.3 (0.3) 0.22
Storage time of samples (months)a 24 (1.5) 28.2 (2.9) 21.5 (1.7) 0.05
Time since last seizure (hours)d 225 (82) 200 (63) 239 (122) 0.82
Time for CX sampling (min)e 188.3 (7.1) 184.8 (10.3) 190 (9.7) 0.71
Time for AMY/HIP sampling (min)f 260.1 (10.0) 254.6 (16.9) 262.8 (12.8) 0.78
Time of HIP manipulation (min)g 11.2 (0.9) 11.7 (1.3) 11.1 (1.2) 0.70
Abbreviations: AMY, amygdala; CX, middle temporal neocortex gyrus; HIP, hippocampus; MRI, magnetic resonance imaging; QOLIE-31, Quality of Life in
Epilepsy Inventory-31. aTime course since brain tissue sampling and the homogenization for neurochemical evaluation (range 8 to 39 months). bAnxiety
disorders: generalized anxiety disorder (two patients in the non-dexamethasone group), social phobia (one patient in non-DEX group). cOther psychiatric
conditions: three patients with dysphoric disorder of epilepsy (one in the non-DEXA group), two patients with postictal psychosis (in the non-DEXA group),
one patient with postictal anxiety (in the DEXA group). dTime course since the last seizure attack occurrence and brain tissue sampling (range 12 to 590 h). eTime
course since anesthesia induction until CX tissue sampling (range 119 to 255 min). fTime course since anesthesia induction until AMY/HIP tissue sampling (range
160 to 360 min). gTime course since HIP vessels thermo-coagulation started until the complete resection of the HIP (range 5 to 25 min). Variables showing a 'P'
level of significance o0.15 are in bold.
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DEXA. There was a trend higher P-GluA1-Ser845 levels in the CX
(P= 0.02), but not in the HIP and AMY of DEXA-treated patients
(Table 3).
The Supplementary Figure 2a shows a dose-dependent effect of
DEXA on P-GluA1-Ser831 levels in the AMY (r= 0.69; r2 = 0.48;
P= 0.0002). Because the non-normal distribution of DEXA dose
related to patients who did not receive DEXA, a linear regression
also was performed only with patients who received DEXA (n= 21;
Supplementary Figure 2b). This analysis confirmed the dose-
dependent decrease of P-GluA1-Ser831 levels in the AMY by DEXA
treatment (r= 0.66; r2 = 0.43; P= 0.002). The observed association
was not affected by the order of surgery (P= 0.79), reducing the
possibility of non-identified confounders related to tissue
sampling of non-DEXA group (data not shown).
To exclude confounding biases resulting from imbalances in the
distribution of gender, AEDs regimen, phenobarbital use, frequency
of seizures, intraoperative serum glucose and storage time of
samples, the association between the AMY levels of P-GluA1-Ser831
and these variables were analyzed together with DEXA treatment.
There were trends for association between AMY levels of P-GluA1-
Ser831 and gender (P=0.02) and serum glucose (P=0.12) (top of
Table 3). After a multiple linear regression (bottom of Table 3), only
DEXA treatment remained independently associated with P-GluA1-
Ser831 levels in AMY. The trend for association between DEXA
treatment and P-GluA1-Ser831 and P-GluA1-Ser845 levels in the CX
and P-GluA1-Ser845 levels in the HIP became non-significant
(P40.15) after controlling for imbalances in the clinical variables
distribution by multiple linear regressions (data not shown).
The rapid effect of DEXA on the AMY levels of P-GluA1-Ser831
could be non-genomic changes on the PKC activity and P-CaMKII
levels, or imbalance of PP1 levels between DEXA and non-DEXA
groups. Table 4 shows that DEXA treatment decreases the mean
levels of P-CaMKII in the AMY (P= 0.02) by 22.4%, despite a trend
(P= 0.08) for higher levels of the total CaMKII in the DEXA treated
patients. There were no differences in the PP1ca levels or PKC
activity in the AMY between DEXA and non-DEXA groups. DEXA
also had no effect on the AMY levels of PKA activity, P-ERK1,
P-ERK2, P-JNK1, P-JNK2, P-AKT and P-p38 (P40.29), excluding a
non-specific effect of DEXA on kinases in general.
MTLE-HS patients show a variable degree of AMY neuronal loss
and gliosis.54 We controlled the AMY levels of total GluA1
subunits. Variations in the astrogliosis were controlled determin-
ing the levels of GFAP and astrocytes glutamate transporters
(EAAT1/2). There were no differences in the AMY levels of GluA1
subunits, GFAP, EAAT1 and 2 between DEXA and non-DEXA
groups (Table 4). Representative western blot results are shown in
the Supplementary Figure 3.
DISCUSSION
To the best of our knowledge, this is the first report showing the
GC effects on synaptic neuroplasticity biomarkers in the human
limbic system. We show that 4 h after a high dose of DEXA the
AMY levels of P-GluA1-Ser831, but not P-GluA1-Ser845, decrease
significantly in MTLE-HS patients. These findings indicate that
DEXA treatment shifts the serine 831 residue of the GluA1-AMPAR
to a dephosphorylated state in the AMY. Notably, in the same
structure we also observed a reduction in the levels of P-CaMKII
(Thr286), indicating a reduction in the autonomous activity of
CaMKII activity.32,58,59 DEXA did not affect the PKC activity or
PP1ca levels in AMY.
The effects could not be attributed to imbalances in the
distribution of demographic, clinical, radiological, intraoperative
and neurochemical variables of our patients. A trend for lower
levels of P-GluA1-Ser831 was also observed in the HIP and CX, but
the possibility of a false negative result related to the small sample
size cannot be completely ruled out.
The AMY is particularly sensitive to rapid responses to GC both
in animals60,61 and in man.62 Furthermore, in an ex vivo rodent
study, using lower concentrations of exogenous GC than in the
current study, we have shown that both a stressor or the
administration of exogenous GC affects both the physiology of
AMPARs and neuroplasticity.40 Brief restraint or DEXA administra-
tion to rats increases the surface expression of GluA1 (but not the
GluA2 subunit) and the magnitude of electrically induced LTP in
the HIP. Furthermore, 60 min after the restraint stress or slice
incubation with corticosterone or DEXA for 30 min the serine 845
residue phosphorylation levels of the of GluA1 subunit increases in
the HIP. The effect is dependent on GC receptors and PKA, but
independent of NMDARs.40 Corticosterone increases GluA2-
AMPAR surface mobility in a time-dependent manner (peak in
15 min), thereby conditioning the extent to which chemical LTP
stimuli effectively increase GluA2 synaptic content during synaptic
potentiation in the HIP.39 In addition, corticosterone also increases
GluA1-AMPAR surface trafficking.39 The phosphorylation state of
Ser831 and Ser845 of GluA1-AMPAR was variable according to
different studies, depending on the brain region, stress type
applied or duration and sampling time after stress.63
Karst et al.64 described that the exposure to two pulses of
corticosterone (10 to 20 min pulse duration with 1 to 3 h pulse
interval) enhances the miniature excitatory postsynaptic currents
(mEPSC) frequency in CA1 pyramidal cells of mice. By contrast,
basolateral amygdala (BLA) neurons responded to the first pulse
with increased mEPSC frequency, but with a decreased mEPSC
frequency to a second pulse. Furthermore, in BLA cells from mice
exposed to restraint stress before slice preparation, corticosterone
Table 2. Comparison of phospho-GluA1-Ser831 and phospho-GluA1-Ser845 levels variation in the middle temporal neocortex, amygdala and head
of the hippocampus according to dexamethasone treatment
Variables All cases, n=31, mean (s.e.) No dexamethasone, n= 11, mean (s.e.) Dexamethasone, n= 20, Mean (s.e.) P-value
Middle temporal neocortex
P-GluA1-Ser831 118.6 (3.2) 126.9 (6.3) 114.3 (3.2) 0.06a
P-GluA1-Ser845 112.4 (3.0) 103.1 (4.1) 117.3 (3.6) 0.02b
Amygdala
P-GluA1-Ser831 109.3 (3.0) 122.8 (4.6) 101.9 (2.8) 0.0003c
P-GluA1-Ser845 108.1 (3.3) 108.2 (6.0) 108.0 (4.1) 0.98
Hippocampus
P-GluA1-Ser831 97.0 (3.7) 105.2 (7.2) 92.5 (4.0) 0.10d
P-GluA1-Ser845 104.2 (3.6) 100.5 (7.8) 106.3 (3.7) 0.46
aNon-significant trend of 12.6% decrease in the neocortex levels of P-GluA1-Ser831; bNon-significant trend of 14.2% decrease in the neocortex levels of
P-GluA1-Ser845; cSignificant decrease of 20.9% in the amygdala levels of P-GluA1-Ser831; dNon-significant trend of 12.7% decrease in the hippocampus levels
of P-GluA1-Ser831.
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rapidly decreased mEPSC frequency, an effect that is dependent
on the non-genomic activation of mineralocorticoid receptors.
Although cross-species implications can be problematical, it is
certainly worth pointing out that our subjects would undoubtedly
have had some degree of pre-surgical hospitalization stress
prior to receiving DEXA with subsequent reduction of the AMY
levels of P-GluA1-Ser831. This is a neurochemical marker which
has been associated with the synaptic depotentiation to the
naive state from a potentiated state. Interestingly, compatible
with a rapid non-transcriptional effect, Lovallo et al.65 showed
a reduction of the BOLD signals in both the AMY and HIP
15–18 min after the injection of a small hydrocortisone dose. The
relationship between this GC-related effect on BOLD signal and
the synaptic potentiation or AMPA phosphorylation state in the
limbic system is unknown. The AMY is a central structure in the
processing of emotional components of memory, coding social
and biological meanings of events.66–70 Clinical findings suggest
that the AMY is necessary for modulating negative and positive
arousing stimuli during encoding, indicating its involvement in
processing biologically relevant stimuli independently of their
valence.67,68 These hypotheses received support by recent
findings showing the BLA is a site of divergence for circuits
mediating positive and negative emotional or motivational
valence.69 The role of GC on the synaptic plasticity of neurons
participating in the positive and negative valence-circuits deserve
further investigation.
The results help not only to understand the mechanisms
involved in the human brain modulation by the stress hormones,
but also the common side effects related to a worldwide
frequently prescribed class of pharmaceuticals. The DEXA dose
used in our patients (or an equipotent dose of other GC) is
commonly used in clinical practice. A large study examining the
effects of oral GC treatment (n= 786 868 courses) showed an
overall incidence of 15.7 per 100 person-years at risk of adverse
neuropsychiatric outcomes, and 22.2 per 100 person-years at risk
for patients on their first course of GC13 The outcomes included
depression, delirium, mania, panic disorder and suicidal behavior.
Considering the critical role of the GluA1 phosphorylation at
Ser831 and Ser845 sites for in vivo synaptic plasticity,18,25,37 we
believe the observed effect of DEXA in the limbic system of our
patients may be, at least in part, related to the high incidence of
adverse neuropsychiatric side-effects during GC treatments. This
hypothesis is in agreement with a previous study showing the
association between the GRIA1 gene, that encode the GluR1
AMPAR, and psychiatric disorders. A combined linkage analysis of
60 families from National Institute of Mental Health Bipolar
Genetics Initiative (NIMH-BPGI) suggested an association between
a SNP in the second intron on the GRIA1 gene and psychotic
bipolar disorder.71 A case–control study showed that two specific
polymorphisms for the GRA1 were associated with schizophrenia
in Italians.72
Recently the role of the dually phosphorylated GluR1 AMPAR at
S831 and S845 on synaptic plasticity was questioned by Hosokawa
et al.73 Using Phos-tag SDS-PAGE they found the majority of
synapses did not contain any phosphorylated AMPAR and the
amount of phosphorylated GluA1 was very low. Although the
neuronal stimulation (chemical LTP) and learning (inhibitory
avoidance) increased phosphorylation, the proportion also was
still low. In contrast, Diering et al.74 using a variety of
measurement methods, showed a large fraction of synapses
positive for phospho-GluA1–containing AMPARs, were highly
responsive to numerous physiologically relevant ‘in vivo’ and
‘in vitro’ stimuli. Their results support the large body of research
indicating a prominent role of GluA1 phosphorylation in synaptic
plasticity. This controversy has no implications for the analysis of
our results because we demonstrated significant changes in the
percentage of the GluA1 subunit phosphorylation that was
Table 3. Variables associated with amygdala levels of phospho-GluA1-Ser831




Male 117.4 (4.5) 0.02a
AEDs regimen
Monotherapy 114 (5.0)
Two AEDs or more 109 (3.9) 0.51a
Phenobarbital treatment
No 111.7 (3.8)
Yes 105.4 (4.9) 0.32a
B r r2 P-value
Univariate linear regressions
Monthly seizure frequency − 0.71 0.21 0.05 0.26b
Serum glucose − 0.19 0.32 0.10 0.12b
Storage time of samples (months) 0.36 0.19 0.04 0.30b
Dexamethasone dose (mg kg− 1) − 145.6 0.69 0.48 0.00002b
Multiple linear regression
Constant 134.8 o0.00001
Female − 0.90 0.85
Serum glucose − 0.10 0.33
Dexamethasone dose (mg kg− 1) −131.1 0.0003
0.73 0.53 0.001c
Abbreviation: AEDs, antiepileptic drugs. aUnivariate analysis by Student’s t-test; bUnivariate analysis by linear regression; cLevel of significance for the multiple
linear regression model.
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controlled for the total amount of phosphorylated AMPAR in both
investigated groups.
There are, of course, limitations to our study. We cannot exclude
the observed effects of DEXA could be, at least to some degree,
related to the epilepsy background and the related pathologic,
clinical and pharmacological variables not occurring in people
without epilepsy. The possibility of false negatives resulting from
the relatively small sample size and the limitation to one single
time point for tissue sampling need to be considered. This
limitation is inherent to western blot studies applied to proteins
phosphorylation analysis in which all samples must be homo-
genized in the same day and conditions to avoid significant inter-
day variability. The inclusion of different time points of DEXA
treatment is not clinically feasible considering the patients receive
the DEXA treatment at the anesthesia induction and the tissue
sampling was dependent of the time of surgery itself. The results
come from patients with an epileptic syndrome showing structural
and functional neuroplasticity changes including a variable loss of
neurons and gliosis in the analyzed structures.42,75 The possible
imbalances of structural changes between the investigated groups
were controlled by corrections for the protein amount, distribution
of gliosis markers, glutamate transporters and glutamate subunit
receptors. The criticism about the non-use of a classic randomiza-
tion is minimized because: (i) patients were included consecutively
and the treatment allocation was not based on any predetermined
variable or specific clinical indication and; (ii) data collection
was done in a prospective way, under exhaustive cautions about
the confounding variables following a predetermined approved
research protocol.
To summarize, a single high dose of i.v. DEXA reduces
significantly the levels of P-CaMKII and P-GluA1-Ser831 in the
AMY of MTLE-HS patients in a dose-dependent manner. These
effects on the signal transduction molecules and synaptic
neuroplasticity in the limbic system contribute to a better
understanding the GC effects in the human brain under
physiologic and pharmacologic conditions.
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